SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 170,734.47 |
| Enterprise Value ($M) | 218,860.47 |
| Book Value ($M) | 5,877.00 |
| Book Value / Share | 10.94 |
| Price / Book | 29.05 |
| NCAV ($M) | -56,932.00 |
| NCAV / Share | -105.98 |
| Price / NCAV | -3.00 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.06 |
| Return on Assets (ROA) | 0.04 |
| Return on Equity (ROE) | 0.66 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.95 |
| Current Ratio | 1.26 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 29,030.00 |
| Assets | 91,839.00 |
| Liabilities | 85,962.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 33,424.00 |
| Operating Income | 10,094.00 |
| Net Income | 4,090.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 11,490.00 |
| Cash from Investing | -1,046.00 |
| Cash from Financing | -9,415.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Vanguard Group Inc | 9.16 | 2.02 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 968,326 | 3,125,827 | 30.98 | |
| 619,783 | 2,198,683 | 28.19 | |
| 559,645 | 1,720,759 | 32.52 | |
| 856,943 | 3,058,964 | 28.01 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ALLO – Allogene Therapeutics, Inc. | ALNY – Alnylam Pharmaceuticals, Inc. |
| ALXO – ALX Oncology Holdings Inc. | AMLX – Amylyx Pharmaceuticals, Inc. |
| AMPH – Amphastar Pharmaceuticals, Inc. |